PPCB (NASDAQ:PPCB) Short Interest Update

PPCB (NASDAQ:PPCB) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 523,788 shares, an increase of 159.7% from the April 15th total of 201,708 shares. Based on an average daily trading volume, of 2,428,344 shares, the days-to-cover ratio is currently 0.2 days. Currently, 4.6% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised PPCB from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, PPCB currently has an average rating of “Sell”.

PPCB Stock Performance

Shares of PPCB opened at $0.07 on Friday. The stock has a market capitalization of $1.16 million, a PE ratio of -0.01 and a beta of 3.59. PPCB has a 52 week low of $0.07 and a 52 week high of $10.81. The stock has a 50-day moving average of $0.11.

Shares of PPCB are set to reverse split on the morning of Monday, May 18th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, May 17th.

PPCB (NASDAQ:PPCB) last announced its earnings results on Thursday, May 14th. The company reported ($0.28) EPS for the quarter.

About PPCB

Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.